Time-dependent biochemical response after middle cerebral artery occlusion in rats: A pilot study

Authors

DOI:

Keywords

ischaemic stroke, middle cerebral artery occlusion, oxidative stress, inflammation

Correspondence

Asma Parveen
Email: asmap9575@gmail.com

Publication history

Received: 29 Mar 2026
Accepted: 20 June 2026
Published online: 2 Aug 2026 

Responsible editor

Reviewers

B: Anonymous
E: Anonymous

Funding

None

Ethical approval

Approved by Institutional Ethics Committee, Saveetha Medical College, Saveetha Institute of Medical Sciences. (Ref No: 1183/PO/Re/S/08/CPCSEA, dated 20 Oct 2023).

Trial registration number

Not available 

Copyright

© The Author(s) 2026; all rights reserved. 
Published by Bangladesh Medical University (former Bangabandhu Sheikh Mujib Medical University).
Key messages
In a rat model of transient occlusion of the middle cerebral artery for 20, 30, or 60 minutes; the 60-minute duration produced the most pronounced, statistically significant shifts in oxidative-stress, inflammatory, and vascular-repair markers, identifying it as the ischaemic duration most likely to reveal meaningful biological change in future studies.

Ischaemic stroke outcome depends largely on how quickly and severely brain tissue is injured before blood flow is restored [1]. Because occlusion duration is one of the few variables clinicians can influence through faster recanalisation, understanding how it shapes the biology of injured tissue is central to defining a realistic treatment window and identifying biomarkers of urgency. Rodent’s middle cerebral artery occlusion, with varying occlusion duration, allows comparison of biochemical and histological responses across ischaemic severities [2, 3]. However, whether occlusion duration differentially affects oxidative-stress, inflammatory, and neurovascular-repair markers within the same 24-hour post-reperfusion window, and whether such changes precedes visible structural injury, remain unclear. This pilot study, consistent with the 3Rs principle of Reduction, screened 20-, 30-, and 60-minute occlusion durations to identify which produces a reproducible, well-tolerated injury profile suitable for an adequately powered main study. Group size followed the 3Rs principle of Reduction rather than a power calculation.

Six adult male Wistar rats (250–300 g) were randomly allocated to three groups (2 in each group), each undergoing right middle cerebral artery oclusion for a fixed duration of 20, 30, or 60 minutes using the intraluminal filament model. Rats were anaesthetised with isoflurane and maintained on a homeothermic pad (37±0.5°C). A silicone-coated monofilament was advanced via the external carotid artery to occlude the MCA origin, confirmed by a regional cerebral blood flow reduction of at least 80%. Reperfusion was achieved by filament withdrawal. Investigators performing assays and histology were blinded. All six rats survived to the 24-hour endpoint, when tissue was collected under terminal anaesthesia. Ipsilateral cortical/striatal tissue was homogenised in radioimmuno-precipitation assay buffer, and total protein was quantified by bicinchoninic acid assay. GSH-Px and superoxide dismutase activity and IL-1β and IL-6 concentrations were measured using activity assays/ELISA (normalised to total protein), and NRP-1 expression was assessed by Western blot (normalised to β-actin). Paraffin-embedded coronal sections were stained with haematoxylin and eosin and scored (20×, three fields/section) for percentage hemisphere involvement (oedema-corrected), pyknosis, vacuolation, and gliosis (0–4 scale).

ANOVA was done to find out overall differences among groups; then pairwise comparisons (unpaired t test) were Bonferroni-corrected for three comparisons per marker (adjusted threshold < 0.017).

Haematoxylin and eosia staining showed comparable mild ischaemic changes across all three groups, with no group showing qualitatively more severe histological injury than another. Biochemical findings are summarised in Table 1. GSH-Px and NRP-1 were significantly higher, and IL-1β significantly lower, in the 60-minute group than in shorter-duration groups. Superoxide dismutase showed a distinct, non-monotonic pattern, peaking at 30 minutes rather than changing progressively with duration. IL-6 was significantly higher at 60 minutes than at 30 minutes, though its difference from 20 minutes narrowly missed significance after correction. As each group comprised a separate pair of animals rather than repeated measurements, these results describe differences between independent occlusion-durations.

Table 1 Mean (standard deviation) of biochemical marker levels in ipsilateral tissue in three groups (two rats per group) with middle cerebral artery occlusion 

Marker

Group 1

(20 min)

Group 2

(30 min)

Group 3

(60 min)

 P

GSH-Px (U/mg protein)

315.4 (6.9)

335.5 (9.4)

407.3 (3.8)a

<0.01

SOD (U/mg protein)

79.3 (1.5)

123.4 (3.5)b

88.3 (2.6)

<0.001

IL-1β (pg/mg protein)

122.1 (4.4)

115.4 (4.4)

61.0 (1.4)a

<0.001

IL-6 (pg/mg protein)

9.6 (0.3)

10.1 (0.0)

12.0 (0.3)c

<0.01

NRP-1 (relative expression)

398.7 (11.2)

403.2 (10.6)

502.6 (3.7)a

<0.01

GSH-Px indicates glutathione peroxidase; SOD, superoxide dismutase; IL, interleukin; NRP-1, Neuropilin-1.

aGroup 1 vs Group 3 and Group 2 vs Group 3 both significant (P<0.05, Bonferroni-corrected). bGroup 2 significantly higher than both Group 1 and Group 3 (P<0.05). cGroup 2 vs Group 3 significant (P<0.05)

These findings suggest occlusion duration differentially engages oxidative-stress, inflammatory, and vascular-repair pathways before injury is apparent on routine histology, consistent with the broader molecular cascade described for ischaemic stroke [4]. 

The rise in GSH-Px and NRP-1 alongside the fall in IL-1β at 60 minutes may reflect a compensatory antioxidant and pro-angiogenic response intensifying with longer ischaemic exposure, in line with neuropilin-1's established role in regulating vascular permeability during ischaemic injury [5]. The concurrent rise in IL-6 at 60 minutes may further reflect duration-dependent inflammatory signaling as previously implicated in stroke severity [6]. Nonetheless, the non-monotonic superoxide dismutase peak at 30 minutes could mark an intermediate threshold at which enzymatic defences are maximally recruited before being overwhelmed, consistent with the engagement of both injury and endogenous protective pathways described in the wider literature [7, 8]. Because biochemical change appears to precede structural injury, such markers could eventually help identify tissue still amenable to intervention before infarction is established. However, this pilot cannot establish that on its own. Given the small sample (2 per group), absence of control group, single timepoint, and non-standardised biochemical assay protocols across the groups, these results need confirmation in an adequately powered study.

As a screening pilot, these results are best used to inform the design of the main study rather than as a stand-alone conclusion. The 60-minute duration produced the most consistent and significant shifts across GSH-Px, NRP-1, and IL-1β without a corresponding increase in histological severity, making it a reasonable candidate duration to carry forward. Superoxide dismutase's distinct and non-monotonic response in the 30-minute group is also worth retaining as a comparison arm.

Variables  

Frequency (%)

Indication of colposcopy

 

Visual inspection of the cervix with acetic acid positive

200 (66.7)

Abnormal pap test

13 (4.3)

Human papilloma virus DNA positive

4 (1.3)

Suspicious looking cervix

14 (4.7)

Others (per vaginal discharge, post-coital bleeding)

69 (23.0)

Histopathological diagnosis

Cervical Intraepithelial Neoplasia 1

193 (64.3)

Cervical Intraepithelial Neoplasia 2

26 (8.7)

Cervical Intraepithelial Neoplasia 3

32 (10.7)

Invasive cervical cancer

27 (9.0)

Chronic cervicitis

17 (5.6)

Squamous metaplasia

5 (1.7)

Groups based on pre-test marks

Pretest
marks (%)

Posttest

Marks (%)

Difference in pre and post-test marks (mean improvement)

P

Didactic lecture classes

<50%

36.6 (4.8)

63.2 (9.4)

26.6

<0.001

≥50%

52.8 (4.5)

72.4 (14.9)

19.6

<0.001

Flipped classes

<50%

36.9 (4.7)

82.2 (10.8)

45.4

<0.001

≥50%

52.8 (4.6)

84.2 (10.3)

31.4

<0.001

Data presented as mean (standard deviation)

Background characteristics

Number (%)

Age at presentation (weeks)a

14.3 (9.2)

Gestational age at birth (weeks)a

37.5 (2.8)

Birth weight (grams)a

2,975.0 (825.0)

Sex

 

Male

82 (41)

Female

118 (59)

Affected side

 

Right

140 (70)

Left

54 (27)

Bilateral

6 (3)

Delivery type

 

Normal vaginal delivery

152 (76)

Instrumental delivery

40 (20)

Cesarean section

8 (4)

Place of delivery

 

Home delivery by traditional birth attendant

30 (15)

Hospital delivery by midwife

120 (60)

Hospital delivery by doctor

50 (25)

Prolonged labor

136 (68)

Presentation

 

Cephalic

144 (72)

Breech

40 (20)

Transverse

16 (8)

Shoulder dystocia

136 (68)

Maternal diabetes

40 (20)

Maternal age (years)a

27.5 (6.8)

Parity of mother

 

Primipara

156 (78)

Multipara

156 (78)

aMean (standard deviation), all others are n (%)

Background characteristics

Number (%)

Age at presentation (weeks)a

14.3 (9.2)

Gestational age at birth (weeks)a

37.5 (2.8)

Birth weight (grams)a

2,975.0 (825.0)

Sex

 

Male

82 (41)

Female

118 (59)

Affected side

 

Right

140 (70)

Left

54 (27)

Bilateral

6 (3)

Delivery type

 

Normal vaginal delivery

152 (76)

Instrumental delivery

40 (20)

Cesarean section

8 (4)

Place of delivery

 

Home delivery by traditional birth attendant

30 (15)

Hospital delivery by midwife

120 (60)

Hospital delivery by doctor

50 (25)

Prolonged labor

136 (68)

Presentation

 

Cephalic

144 (72)

Breech

40 (20)

Transverse

16 (8)

Shoulder dystocia

136 (68)

Maternal diabetes

40 (20)

Maternal age (years)a

27.5 (6.8)

Parity of mother

 

Primipara

156 (78)

Multipara

156 (78)

aMean (standard deviation), all others are n (%)

Mean escape latency of acquisition day

Groups                 

NC

SC

ColC

Pre-SwE Exp

Post-SwE Exp

Days

 

 

 

 

 

1st

26.2 (2.3)

30.6 (2.4) 

60.0 (0.0)b

43.2 (1.8)b

43.8 (1.6)b

2nd

22.6 (1.0) 

25.4 (0.6)

58.9 (0.5)b

38.6 (2.0)b

40.5 (1.2)b

3rd

14.5 (1.8) 

18.9 (0.4) 

56.5 (1.2)b

34.2 (1.9)b 

33.8 (1.0)b

4th

13.1 (1.7) 

17.5 (0.8) 

53.9 (0.7)b

35.0 (1.6)b

34.9 (1.6)b

5th

13.0 (1.2) 

15.9 (0.7) 

51.7 (2.0)b

25.9 (0.7)b 

27.7 (0.9)b

6th

12.2 (1.0) 

13.3 (0.4) 

49.5 (2.0)b

16.8 (1.1)b

16.8 (0.8)b

Average of acquisition days

5th and 6th 

12.6 (0.2)

14.6 (0.8)

50.6 (0.7)b

20.4 (2.1)a

22.4 (3.2)a

NC indicates normal control; SC, Sham control; ColC, colchicine control; SwE, swimming exercise exposure.

aP <0.05; bP <0.01.

Categories

Number (%)

Sex

 

   Male

36 (60.0)

   Female

24 (40.0)

Age in yearsa

8.8 (4.2)

Education

 

   Pre-school

20 (33.3)

   Elementary school

24 (40.0)

   Junior high school

16 (26.7)

Cancer diagnoses

 

Acute lymphoblastic leukemia

33 (55)

Retinoblastoma

5 (8.3)

Acute myeloid leukemia

4 (6.7)

Non-Hodgkins lymphoma

4 (6.7)

Osteosarcoma

3 (5)

Hepatoblastoma

2 (3.3)

Lymphoma

2 (3.3)

Neuroblastoma

2 (3.3)

Medulloblastoma

1 (1.7)

Neurofibroma

1 (1.7)

Ovarian tumour

1 (1.7)

Pancreatic cancer

1 (1.7)

Rhabdomyosarcoma

1 (1.7)

aMean (standard deviation)

Test results

Disease

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

Yes

No

Reid’s score ≥ 5

Positive

10

15

37.0

94.5

40.1

93.8

Negative

17

258

 

 

 

 

Swede score ≥ 5

Positive

20

150

74.1

45.0

11.8

94.6

Negative

7

123

 

 

 

 

Swede score ≥ 8

Positive

3

21

11.1

92.3

12.5

91.3

Negative

24

252

 

 

 

 

High-grade indicates a score of ≥5 in both tests; PPV indicates positive predictive value; NPV, negative predictive value

Test

Sensitivity (%)

Specificity (%)

Positive predictive value (%)

Negative predictive value (%)

Reid’s score ≥ 5

37.0

94.5

40.0

93.8

Swede score ≥ 5

74.1

45

11.8

94.6

Swede score ≥ 8

11.1

92.3

12.5

91.3

Test

Sensitivity (%)

Specificity (%)

Positive predictive value (%)

Negative predictive value (%)

Reid’s score ≥ 5

37.0

94.5

40.0

93.8

Swede score ≥ 5

74.1

45

11.8

94.6

Swede score ≥ 8

11.1

92.3

12.5

91.3

Narakas classification

Total

200 (100%)

Grade 1

72 (36%)

Grade 2

64 (32%)

Grade 3

50 (25%)

Grade 4

14 (7%)

Complete recoverya

107 (54)

60 (83)

40 (63)

7 (14)

-

Near complete functional recovery but partial deformitya

22 (11)

5 (7)

10 (16)

6 (12)

1 (7)

Partial recovery with gross functional defect    and deformity

31 (16)

7 (10)

13 (20)

10 (20)

1 (7)

No significant improvement 

40 (20)

-

1 (1.5)

27 (54)

12 (86)

aSatisfactory recovery

bGrade 1, C5, 6, 7 improvement; Grade 2, C5, 6, 7 improvement; Grade 3, panpalsy C5, 6, 7, 8, 9, Grade 4, panpalsy with Hornon’s syndrome.

Narakas classification

Total

200 (100%)

Grade-1

72 (36%)

Grade-2

64 (32%)

Grade-3

50 (25%)

Grade-4

14 (7%)

Complete recoverya

107 (54)

60 (83)

40 (63)

7 (14)

-

Near complete functional recovery but partial deformitya

22 (11)

5 (7)

10 (16)

6 (12)

1 (7)

Partial recovery with gross functional defect    and deformity

31 (16)

7 (10)

13 (20)

10 (20)

1 (7)

No significant improvement 

40 (20)

-

1 (1.5)

27 (54)

12 (86)

aSatisfactory recovery

bGrade 1, C5, 6, 7 improvement; Grade 2, C5, 6, 7 improvement; Grade 3, panpalsy C5, 6, 7,8,9, Grade 4, panpalsy with Hornon’s syndrome.

Variables in probe trial day

Groups

NC

SC

ColC

Pre-SwE Exp

Post-SwE Exp

Target crossings

8.0 (0.3)

7.3 (0.3) 

1.7 (0.2)a

6.0 (0.3)a

5.8 (0.4)a

Time spent in target

18.0 (0.4) 

16.2 (0.7) 

5.8 (0.8)a

15.3 (0.7)a

15.2 (0.9)a

NC indicates normal control; SC, Sham control; ColC, colchicine control; SwE, swimming exercise exposure.

aP <0.01.

Pain level

Number (%)

P

Pre

Post 1

Post 2

Mean (SD)a pain score

4.7 (1.9)

2.7 (1.6)

0.8 (1.1)

<0.001

Pain categories

    

   No pain (0)

-

(1.7)

31 (51.7)

<0.001

   Mild pain (1-3)

15 (25.0)

43 (70.0)

27 (45.0)

 

   Moderete pain (4-6)

37 (61.7)

15 (25.0)

2 (3.3)

 

   Severe pain (7-10)

8 (13.3)

2 (3.3)

-

 

aPain scores according to the visual analogue scale ranging from 0 to 10; SD indicates standard deviation

Surgeries

Number  

(%)

Satisfactory outcomes n (%)

Primary surgery (n=24)

 

 

Upper plexus

6 (25)

5 (83)

Pan-palsy

18 (75)

6 (33)

All

24 (100)

11 (46)

Secondary Surgery (n=26)

 

 

Shoulder deformity

15 (58)

13 (87)

Wrist and forearm deformity

11 (42)

6 (54)

All

26 (100)

19 (73)

Primary and secondary surgery

50 (100)

30 (60)

Mallet score 14 to 25 or Raimondi score 2-3 or Medical Research grading >3 to 5.

Narakas classification

Total

200 (100%)

Grade-1

72 (36%)

Grade-2

64 (32%)

Grade-3

50 (25%)

Grade-4

14 (7%)

Complete recoverya

107 (54)

60 (83)

40 (63)

7 (14)

-

Near complete functional recovery but partial deformitya

22 (11)

5 (7)

10 (16)

6 (12)

1 (7)

Partial recovery with gross functional defect    and deformity

31 (16)

7 (10)

13 (20)

10 (20)

1 (7)

No significant improvement 

40 (20)

-

1 (1.5)

27 (54)

12 (86)

aSatisfactory recovery

bGrade 1, C5, 6, 7 improvement; Grade 2, C5, 6, 7 improvement; Grade 3, panpalsy C5, 6, 7,8,9, Grade 4, panpalsy with Hornon’s syndrome.

Trials

Groups

NC

SC

ColC

Pre-SwE Exp

Post-SwE Exp

1

20.8 (0.6)

22.1 (1.8)

41.1 (1.3)b

31.9 (1.9)b

32.9 (1.8)a, b

2

10.9 (0.6)

14.9 (1.7)

37.4 (1.1)b

24.9 (2.0)b

26.8 (2.5)b

3

8.4 (0.5)

9.9 (2.0)

32.8 (1.2)b

22.0 (1.4)b

21.0 (1.4)b

4

7.8 (0.5)

10.4 (1.3)

27.6(1.1)b

12.8 (1.2)b

13.0 (1.4)b

Savings (%)c

47.7 (3.0)

33.0 (3.0)

10.0 (0.9)b

23.6 (2.7)b

18.9 (5.3)b

NC indicates normal control; SC, Sham control; ColC, colchicine control; SwE, swimming exercise exposure.

aP <0.05; bP <0.01.

cThe difference in latency scores between trials 1 and 2, expressed as the percentage of savings increased from trial 1 to trial 2

 Lesion-size

Histopathology report

Total

CIN1

CIN2

CIN3

ICC

CC

SM

0–5 mm

73

0

0

0

5

5

83

6–15 mm

119

18

1

4

0

0

142

>15 mm

1

8

31

23

12

0

75

Total

193

26

32

27

17

5

300

CIN indicates cervical intraepithelial neoplasia; ICC, invasive cervical cancer; CC, chronic cervicitis; SM, squamous metaplasia

 

Histopathology report

Total

CIN1

CIN2

CIN3

ICC

CC

SM

Lesion -Size

0-5  mm

73

0

0

0

5

5

83

6-15  mm

119

18

1

4

0

0

142

>15  mm

1

8

31

23

12

0

75

Total

193

26

32

27

17

5

300

CIN indicates Cervical intraepithelial neoplasia; ICC, Invasive cervical cancer; CC, Chronic cervicitis; SM, Squamous metaplasia

Group

Didactic posttest marks (%)

Flipped posttest marks (%)

Difference in marks (mean improvement)

P

<50%

63.2 (9.4)

82.2 (10.8)

19.0

<0.001

≥50%

72.4 (14.9)

84.2 ( 10.3)

11.8

<0.001

Data presented as mean (standard deviation)

Acknowledgements
We extend our heartfelt gratitude to Saveetha College of Physiotherapy and Saveetha Institute of Medical and Technical Sciences for their constant support and encouragement throughout this research. We are deeply thankful to the management, faculty, and staff for providing the necessary facilities and resources to successfully complete this study.
Author contributions
Conception and design, or design of the research; or the acquisition, analysis, or interpretation of data: AP, PS, LP. Drafting the manuscript or revising it critically for important intellectual content: YU, DP, AP, Ak.T. Final approval of the version to be published: PS, LP. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: AP.
Conflict of interest
We do not have any conflict of interest.
Data availability statement
We confirm that the data supporting the findings of the study will be shared upon reasonable request.
AI disclosure
During the preparation of this manuscript, the author(s) used AI Tools in order to refine the academic language.

Supplementary file
None
    References
    1. Hou S, Zhang Y, Xia Y, Liu Y, Deng X, Wang W, Wang Y, Wang C, Wang G. Global, regional, and national epidemiology of ischaemic stroke from 1990 to 2021. Eur J Neurol. 2024;31(9):e16481. doi: https//doi.org/10.1111/ene.16481
    2. Trotman-Lucas M, Gibson CL. A review of experimental models of focal cerebral ischemia focusing on the middle cerebral artery occlusion model. F1000Research. 2021;10:242. doi: https//doi.org/10.12688/f1000research.51573.1
    3. Sokolowski JD, Soldozy S, Sharifi KA, Norat P, Kearns KN, Liu L, Williams AM, Yagmurlu K, Mastorakos P, Miller GW, Kalani MYS, Park MS, Kellogg RT, Tvrdik P. Preclinical models of middle cerebral artery occlusion: new imaging approaches to a classic technique. Front Neurol. 2023;14:1170675. doi: https//doi.org/10.3389/fneur.2023.1170675
    4. Rehman S, Nadeem A, Akram U, Sarwar A, Quraishi A, Siddiqui H, Malik MAJ, Nabi M, Ul Haq I, Cho A, Mazumdar I, Kim M, Chen K, Sepehri S, Wang R, Balar AB, Lakhani DA, Yedavalli VS. Molecular mechanisms of ischaemic stroke: a review integrating clinical imaging and therapeutic perspectives. Biomedicines. 2024;12(4):812. doi: https//doi.org/10.3390/biomedicines12040812
    5. Domingues A, Fantin A. Neuropilin 1 regulation of vascular permeability signaling. Biomolecules. 2021;11(5):666. doi: https//doi.org/10.3390/biom11050666
    6. Pawluk H, Woźniak A, Tafelska-Kaczmarek A, Kosinska A, Pawluk M, Sergot K, Grochowalska R, Kołodziejska R. The role of IL-6 in ischaemic stroke. Biomolecules. 2025;15(4):470. doi: https//doi.org/10.3390/biom15040470
    7. Meng X, Zheng Z, Yang L, Yang C, Li X, Hao Y. Dynamic mechanisms and targeted interventions in cerebral ischemia–reperfusion injury: pathological cascade from ischemia to reperfusion and promising therapeutic strategies. Front Neurosci. 2025;19:1649533. doi: https//doi.org/10.3389/fnins.2025.1649533
    8. Wu L, Xiong X, Wu X, Ye Y, Jian Z, Zhi Z, Gu L. Targeting oxidative stress and inflammation to prevent ischemia-reperfusion injury. Front Mol Neurosci. 2020;13:28. doi: https//doi.org/10.3389/fnmol.2020.00028